imiglucerase medication used treatment gauchers recombinant dnaproduced analogue human enzyme Î²glucocerebrosidase cerezyme freezedried medicine containing imiglucerase manufactured genzyme corporation given intravenously reconstitution treatment type type gauchers disease available formulations containing units per vial specific activity highly purified human enzyme meanwhile enzyme activity produced recombinant dna technology approximately typical dose every two weeks maximum ukg every two weeks safety established ages one expensive medications annual cost per person united imiglucerase granted orphan drug status united states australia cerezyme one drugs manufactured genzymes allston massachusetts plant production disrupted contamination vesivirus common side effect hypersensitivity occurs patients associated symptoms cough shortness breath rashes itching angiooedema less common side effects include dizziness headache nausea diarrhea reactions injection site found less clinical interaction studies miglustat appears increase clearance imiglucerase resulting decreased enzyme httpsenwikipediaorgwikiimiglucerase